{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HAV&page=46", "query": { "intervention": "HAV", "page": 46 }, "page_size": 10 }, "pagination": { "page": 46, "page_size": 10, "total_count": 1228, "total_pages": 123, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HAV&page=47&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HAV&page=45&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T01:20:16.426Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01846455", "title": "Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatic Failure", "Hepatic Impairment", "Chronic Hepatitis C Infection With Hepatic Coma" ], "interventions": [ { "name": "2.0mg Buprenorphine/0.5mg Naloxone", "type": "DRUG" }, { "name": "Promethazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indivior Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 43, "start_date": "2012-09", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2016-10-24", "last_synced_at": "2026-10-28T01:20:16.426Z", "location_count": 3, "location_summary": "Hialeah, Florida • Orlando, Florida • San Antonio, Texas", "locations": [ { "city": "Hialeah", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01846455" }, { "nct_id": "NCT00015652", "title": "Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Peginterferon alfa-2b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": null, "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-28T01:20:16.426Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00015652" }, { "nct_id": "NCT01316185", "title": "Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis D" ], "interventions": [ { "name": "EBP921", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eiger BioPharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2011-01", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2016-08-08", "last_synced_at": "2026-10-28T01:20:16.426Z", "location_count": 2, "location_summary": "San Francisco, California • Detroit, Michigan", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01316185" }, { "nct_id": "NCT07040319", "title": "Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Glecaprevir/pibrentasvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "16 Years to 45 Years · Female only" }, "enrollment_count": 30, "start_date": "2026-06-25", "completion_date": "2028-03-03", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-28T01:20:16.426Z", "location_count": 10, "location_summary": "Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07040319" }, { "nct_id": "NCT01349465", "title": "3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "No treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 249, "start_date": "2011-07-04", "completion_date": "2016-01-05", "has_results": true, "last_update_posted_date": "2017-04-10", "last_synced_at": "2026-10-28T01:20:16.426Z", "location_count": 12, "location_summary": "Bakersfield, California • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01349465" }, { "nct_id": "NCT01057667", "title": "A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "RO5024048", "type": "DRUG" }, { "name": "Ribavirin [Copegus]", "type": "DRUG" }, { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 168, "start_date": "2010-02", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-28T01:20:16.426Z", "location_count": 19, "location_summary": "La Jolla, California • Bradenton, Florida • Atlanta, Georgia + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01057667" }, { "nct_id": "NCT05070364", "title": "Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis Delta Virus" ], "interventions": [ { "name": "Peginterferon Lambda-1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eiger BioPharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 150, "start_date": "2021-12-21", "completion_date": "2025-01-15", "has_results": false, "last_update_posted_date": "2023-08-25", "last_synced_at": "2026-10-28T01:20:16.426Z", "location_count": 7, "location_summary": "Los Angeles, California • Redwood City, California • San Francisco, California + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05070364" }, { "nct_id": "NCT00861744", "title": "Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rubella", "Mumps", "Measles", "Measles-Mumps-Rubella Vaccine" ], "interventions": [ { "name": "GSK Biological's investigational vaccine 209762", "type": "BIOLOGICAL" }, { "name": "M-M-R® II (Merck and Co)", "type": "BIOLOGICAL" }, { "name": "Varivax®", "type": "BIOLOGICAL" }, { "name": "Havrix®", "type": "BIOLOGICAL" }, { "name": "Prevnar®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 1259, "start_date": "2009-06-03", "completion_date": "2012-06-18", "has_results": true, "last_update_posted_date": "2020-01-03", "last_synced_at": "2026-10-28T01:20:16.426Z", "location_count": 45, "location_summary": "Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Conway", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861744" }, { "nct_id": "NCT00069511", "title": "12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "UT-231B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "United Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 72, "start_date": "2003-07", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-28T01:20:16.426Z", "location_count": 6, "location_summary": "Gainesville, Florida • New Orleans, Louisiana • Boston, Massachusetts + 3 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069511" }, { "nct_id": "NCT05717686", "title": "A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "AHB-137 injection", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AusperBio Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 64, "start_date": "2023-02-28", "completion_date": "2025-01-07", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-10-28T01:20:16.426Z", "location_count": 4, "location_summary": "Redwood City, California • Baltimore, Maryland • New York, New York + 1 more", "locations": [ { "city": "Redwood City", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05717686" } ] }